Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Amgen
Femme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
A Study to Evaluate AMG 162 in the Treatment of Postmenopausal Osteoporosis
The primary objective is to determine whether denosumab (formerly known as AMG 162) treatment can reduce the number of postmenopausal osteoporotic women (BMD T-score below -2.5) with new vertebral fra...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
Expanded Access Study of Talimogene Laherparepvec of Subjects in Europe with late stage Melanoma
To provide access of talimogene laherparepvec for subjects with unresected stage IIIB to IVM1c melanoma in select countries in Europe until marketing authorization approval by the European Commission ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
Study to evaluate evolocumab in people with type 2 diabetes mellitus with high cholesterol (hypercholesterolemia or mixed dyslipidemia). Estudio para evaluar evolocumab en sujetos con diabetes mellitus tipo 2 con colesterol alto (hipercolesterolemia o dislipidemia mixta)
To evaluate the effect, the safety and tolerability of 12 weeks of subcutaneous (SC) evolocumab monthly (QM) compared with placebo QM on percent change from baseline in low-density lipoprotein cholest...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
The purpose of this study is to find out more about the efficacy and safety of denosumab produced by two different processes in postmenopausal women with osteoporosis
The primary objectives of this study are to evaluate 1. whether the efficacy of denosumab (60 mg subcutaneously every 6 months) manufactured by the proposed process referred to as CP4 is not inferio...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
KAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)
MAJ Il y a 5 ans
Compare therapeutic efficacy and safey of AMG 416 and cinacalcet HCl in hemodialysis subjects with secondary hyperparathyroidism
Demonstrate that treatment with AMG 416 is not inferior to treatment with cinacalcet for lowering plasma intact parathyroid hormone (PTH) levels by > 30% from baseline among subjects with chronic kidn...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Psoriasis
To establish a dose-response efficacy profile of AMG 827 compared with placebo as measured by the percent improvement from baseline in Psoriasis Area and Severity Index (PASI) score at week 12 and to ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
A randomised active controlled study of AMG 162 in breast cancer subjects with bone metastases who have not previously been treated with bisphosphonate therapy
To evaluate the effect of different doses and schedules of AMG 162 on the percent change from baseline in urinary N-telopeptide (uNTx) at week 13
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
A Multicenter, Double-blind, Placebo-controlled Roll-over Study to Protocol 20010103 of Darbepoetin Alfa for the Treatment of Anemia of Cancer
To evaluate the safety of darbepoetin alfa beyond 16 weeks of treatment in subjects with anemia of cancer who are not receiving chemotherapy
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Amgen, Inc
MAJ Il y a 5 ans
A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment with Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women with Low Bone Mineral Density
The primary objective of the study is to estimate the effect of denosumab (AMG 162), compared to placebo on cortical thickness at the distal radius, as determined by in-vivo microCT (XtremeCT®) at 12 ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme
Entre 18 ans
et 99 ans
Amgen
MAJ Il y a 5 ans
Étude 20160323 : étude de phase 1 évaluant la sécurité et la tolérance de l’AMG 757 chez des patients ayant un cancer du poumon à petites cellules.
Le cancer du poumon à petites cellules prend naissance dans les cellules qui tapissent les bronches situées au centre des poumons. Il y a deux types principaux de cancer du poumon à petites cellules :...
Pays
France
Organes
Poumon, type à petites cellules
Spécialités
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
Plus d'informations
Précédent
6
7
8
9
10
11
12
13
14
15
Suivant